In an interview on CNBC’s Mad Money, Kevin Hochman said, “We have a higher income guest starting to develop.” He does not see the GLP-1 drugs as a threat to the business. “We’re well positioned if things with GLP-1s change.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EAT:
- Brinker raises FY24 EPS view to $3.35-$3.65 from $3.15-$3.55, consensus $3.32
- Brinker reports Q1 adjusted EPS 28c, consensus 6c
- BRINKER INTERNATIONAL REPORTS FIRST QUARTER OF FISCAL 2024 RESULTS; AND UPDATES FISCAL 2024 GUIDANCE
- EAT Upcoming Earnings Report: What to Expect?
- Brinker price target raised to $33 from $32 at Wedbush